Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survey Results Show How MPNs Impact Life Quality

Ann Hematol; ePub 2017 Aug 5; Harrison, et al

There is a need for improved patient-physician communication, standardized monitoring of symptoms, and agreement on treatment goals in patients with myeloproliferative neoplasms (MPNs), according to results of an online survey involving >900 individuals. Participants included patients with MPNs (n=699) and physicians (n=219). Investigators measured MPN-related symptoms and the impact of MPNs on quality of life, the ability to work, and disease-management strategies. Among the results:

  • The most frequent and severe symptom was fatigue.
  • Most patients experienced reduced quality of life, even those with low symptom burden and low-risk scores.
  • Many reported decreased ability to work and impaired overall activity.
  • Physician feedback and blood counts were the most important indicators of treatment success.
  • Patients often had different treatment goals than physicians.


Harrison C, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: Results from the international MPN Landmark survey. [Published online ahead of print August 5, 2017]. Ann Hematol. doi:10.1007/s00277-017-3082-y.